

NEWS RELEASE

Nov 16, 2020  
TMS Co., Ltd.

**TMS announces completion of patient enrollment  
for TMS-007 acute ischemic stroke Phase IIa clinical study**

Tokyo, Japan, Nov 16, 2020

TMS Co., Ltd. (Fuchu-shi, Tokyo, JAPAN / CEO Takuro Wakabayashi, “TMS”) today announced that the company completed patient enrollment of planned 90 patients in its TMS-007 Phase IIa clinical study for acute ischemic stroke.

This Phase IIa study is a randomized, double-blind, and placebo-controlled study with objectives to assess safety and efficacy of TMS-007 in acute ischemic stroke patients. TMS plans to analyze the data after 90-day observation period.

About TMS-007

TMS-007 belongs to a group of novel small molecule compounds named SMTP, produced by *Stachybotrys Microspora*. The compound has dual mode of action, one is to enhance endogenous clot dissolution activities and the other is to suppress inflammation. This unique combination could position TMS-007 as a best in class thrombolytic for individuals with acute ischemic stroke (AIS) with potential for extended treatment window as compared to current thrombolytic agents (4.5 hours after onset) that could lead to treatment of larger patient population.

Research and development of TMS-007 has been primarily conducted through collaborative relationships between TMS and Tokyo University of Agriculture and Technology, Showa University, and Tohoku University, and has been supported by Japan Science and Technology Agency (JST) and New Energy and Industrial Technology Development Organization (NEDO).

About TMS Co., Ltd.

TMS Co., Ltd. is a privately-held, clinical stage biotechnology company based in Fuchu-shi, Tokyo. The company was founded in 2005 to develop therapeutics based on novel discoveries to modulate fibrinolytic system, identified by a team of scientists at Tokyo University of Agriculture and Technology (TUAT), led by Dr. Keiji Hasumi, Professor of the university and Chief Scientist of TMS. TMS currently develops SMTP compounds as therapeutics for various diseases.

CONTACT

+81-42-306-5078